Physician profile
Robert Rutstein
NPI 1891774915
$3,102.36
in general payments reported to CMS, 2019-2025
20 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $318 · 2021: $121 · 2022: $326 · 2023: $638 · 2024: $890 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $666.16 | 2019-2025 | Augment Injectable, Ortholoc 2 Lapifuse |
| Integra Lifesciences Corporation | $301.19 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $225.13 | 2020-2024 | Stravix, Grafix, Evos |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $169.78 | 2019-2023 | Jublia |
| Solventum Corporation | $149.99 | 2024 | V.A.C. Veraflo Cleanse Choice, Prevena Restor Axioform |
| Osiris Therapeutics INC. | $145.29 | 2019 | |
| Gotham Surgical Solutions & Devices, INC. | $144.27 | 2020 | |
| Organogenesis INC. | $141.12 | 2019-2022 | |
| Zimvie INC. | $136.11 | 2023 | |
| Treace Medical Concepts, INC. | $134.64 | 2024 | |
| Depuy Synthes Sales INC. | $129.62 | 2024 | Motoband, Motoband Cp, Minibunion |
| Kerecis Limited | $120.99 | 2021 | |
| Triad Life Sciences INC. | $118.81 | 2022 | |
| Next Science LLC | $118.39 | 2024 | Surgx, Xperience, Blastx |
| Axogen | $112.44 | 2023 | Avance Nerve Graft |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $99.55 | 2022 | |
| Kci USA, INC. | $91.15 | 2019 | |
| Averitas Pharma INC. | $54.42 | 2023-2024 | Qutenza |
| Sebela Pharmaceuticals INC. | $22.75 | 2023 | Naftin |
| Baxter Healthcare | $20.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rutstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.